RELATIONSHIP BETWEEN BIOMOLECULES ASSOCIATED WITH THE SECRETORY ACTIVITY OF VISCERAL ADIPOCYTES AND ELECTROPHYSIOLOGICAL SIGNS OF METABOLIC CARDIOMYOPATHIES IN PERSONS UNDER 45 YEARS OF AGE

Highlights

• ECG signs of metabolic cardiomyopathies in men aged 25–44 years, regardless of age and waist circumference, are directly associated with the serum adipsin concentration and inversely associated with the concentration of glucagon-like peptide 1 in the blood.
• ECG signs of metabolic cardiomyopathies in women aged 25–44 years are directly associated with the serum c-peptide concentration and inversely associated with the concentration of glucose-dependent insulinotropic polypeptide 1 in the blood.

Abstract

Aim. To study the relationship between electrophysiological signs of metabolic cardiomyopathy (MC) and biomolecules associated with the secretory activity of visceral adipocytes in persons aged 25–44 years residing in Novosibirsk.

Methods. The study included 1 198 subjects. A single-stage survey of a random sample of the 25–44-year-old population of Novosibirsk (49,7% men, 50,3% women) was conducted. During the examination, among other things, a resting 12-lead ECGs was recorded, and later the ECGs were classified according to Minnesota Code categories. Five ECG signs of MC were analysed: 1) ST-segment displaced above baseline (ST-segment elevation); 2) ST-segment displaced below baseline (ST-segment depression); 3) T wave changes; 4) TV1>TV6 patterns and 5) ECG signs of left ventricular hypertrophy. Serum concentrations of biomolecules associated with the secretory activity of visceral adipocytes were determined by multiplex analysis.

Results. The results of multivariate logistic regression analysis showed that the ECG signs of MC in men aged 25–44 years, regardless of age and waist circumference, are directly associated with the serum adipsin concentration (Exp B 1,039, 95% CI 1,002–1,077, p = 0.039) and inversely associated with the concentration of glucagon-like peptide 1 in the blood (Exp B 0.999, 95% CI 0.998–1,000, p = 0.042). ECG signs of MC in women aged 25–44 years are directly associated with the serum peptide concentration (Exp B 1,439, 95% CI 1,082–1,915, p = 0.012) and inversely associated with the concentration of glucose-dependent insulinotropic polypeptide in the blood (Exp B 0.986, 95% CI 0.978–0.995, p = 0.001).

Conclusion. The results obtained reflect the significant influence of these biomolecules associated with the secretory activity of visceral adipocytes on the occurrence of ECG signs of MC in young people aged 25–44 years.

1. Vilkov V.G., Shalnova S.A., Balanova Yu.A. et al. Prevalence of hypotension in populations of the Russian Federation and the United States of America according to 30-year follow-up. Cardiovascular Therapy and Prevention. 2020;19(3):2497 (In Russ.). doi:10.15829/1728-8800-2020-2497

2. Viktorova I.A., Shirlina N.G., Stasenko V.L et al. The prevalence of traditional risk factors for cardiovascular disease in the Omsk region: data of the ESSE-RF2 study. Russian Journal of Cardiology. 2020; 25(6): 3815. (In Russ.). doi:10.15829/1560-4071-2020-3815

3. Cuspidi C., Facchetti R., Bombelli M. et al. High normal blood pressure and left ventricular hypertrophy echocardiographic findings from the PAMELA population. Hypertension. 2019; 73(3):612-9. doi:10.1161/Hypertensionaha.118.12114.

4. He H.J., Lee S., Lee E.K et al. Association of blood pressure components with mortality and cardiovascular events in prehypertensive individuals: a nationwide population-based cohort study. Ann. Med. 2018; 50(5):443-52. https://doi.org/10.1080/07853890.2018.1492146.

5. Heiskanen J.S., Ruohonen S., Rovio S.P., Kyto V. Determinants of left ventricular diastolic function. The Cardiovascular Risk in Young Finns Study. Echocardiography. 2019; 36(5):854-61. doi:10.1111/echo.14321.

6. Zhernakova Yu.V., Zheleznova E.A., Chazova I.E. et al. The prevalence of abdominal obesity and the association with socioeconomic status in Regions of the Russian Federation, the results of the epidemiological study - ESSE-RF. Therapeutic archive. 2018; 90(10):14-22. (In Russ.). doi:10.26442/terarkh2018901014-22

7. Balanova Yu.A., Shalnova S.A., Deev A.D., et al. Obesity in russian population — prevalence and association with the non-communicable diseases risk factors. Russian Journal of Cardiology. 2018;(6):123-130. (In Russ.). doi:10.15829/1560-4071-2018-6-123-130

8. Gromnatsky N.I., Petrova G.D. Heart pathology in young and middle-aged patients with metabolic syndrome. Russian Journal of Cardiology. 2007;(5):24-27. (In Russ.).

9. Landecho MF, Tuero C, Valentí V. et al. Relevance of Leptin and Other Adipokines in Obesity-Associated Cardiovascular Risk. Nutrients. 2019; 11(11): 2664. doi:10.3390/nu11112664.

10. Taylor EB. The complex role of adipokines in obesity, inflammation, and autoimmunity. Clin Sci (Lond). 2021; 135(6): 731-752. doi:10.1042/CS20200895.

11. Antropova O.N., Silkina S.B., Polyakova I.G. et al. Association of hemodynamic parameters and cardiovascular risk factors with cardiac remodeling in young patients with prehypertension and hypertension. Russian Journal of Cardiology. 2020; 25(6):3797. (In Russ.). doi:10.15829/1560-4071-2020-3797

12. Bogatyreva F.M., Kaplunova V.Yu., Kozhevnikova M.V. et al. Correlation between markers of fibrosis and myocardial remodeling in patients with various course of hypertrophic cardiomyopathy. Cardiovascular Therapy and Prevention. 2022;21(3):3140. (In Russ.). doi:10.15829/1728-8800-2022-3140

13. Shishkova V.N., Martynov A.I. Insulin resistance: focus on the pathogenesis of cardiomyopathy. Consilium Medicum. 2020; 22 (10): 52–54. (In Russ.). doi:10.26442/20751753.2020.10.200341

14. Veklich A.S., Koziolova N.A., Karavaev P.G. Cardiovascular remodeling in patients with diabetic сardiomyopathy. Russian Journal of Cardiology. 2019;(11):42-47. (In Russ.). doi:10.15829/1560-4071-2019-11-42-47

15. Muromtseva G.A., Vilkov V.G., Konstantinov V.V. et al. The prevalence of electrocardiographic abnormalities in the Russian population in the early 21st century (the ESSE-RF study). Russian Journal of Cardiology. 2018;(12):7-17. (In Russ.) doi:10.15829/1560-4071-2018-12-7-17

16. Timoshenko N.A., Ragino Yu.I., Voevoda M.I. Metabolic cardiomyopathy. current state of problem. Ateroscleroz. 2013;9(1):65-76. (In Russ.).

17. Kuzminykh N.A., Shcherbakova L.V., Shramko V.S. et al. The association of ECG TV1>TV6 phenomenon as electrophysiological sign of metabolic myocardial disorders with risk factors for ischemic heart disease in the population of 25–44 years. Ateroscleroz. 2021;17(2):22-32. (In Russ.). doi:10.52727/2078-256X-2021-17-2-22-32

18. Kuzminykh N.A., Shcherbakova L.V., Shramko V.S. et al. ST segment elevation and depression, and T-wave changes as electrophysiological signs of metabolic disorders with lipid and non-lipid risk factors for ischemic heart disease in the 25–44-year-old population. Complex Issues of Cardiovascular Diseases. 2021;10(4):29-38. (In Russ.). doi:10.17802/2306-1278-2021-10-4-29-38

19. Kuzminykh N.A., Scherbakova L.V., Shramko V.S. et al. Associations of cardiovascular disease risk factors with electrophysiological signs of myocardial metabolic disorders in young people 25—44 years old. Profilakticheskaya Meditsina. 2021;24(12):49‑56. (In Russ.) doi:10.17116/profmed20212412149

20. Aleksandrov An.A, Shatskaya O.A., Kuharenko S.S. et al. Diabetic cardiomyopathy. Resistin: a control of a myocardial hypertrophy. Rational Pharmacotherapy in Cardiology. 2014; 10(5): 534-539. (In Russ.). doi:10.20996/1819-6446-2014-10-5-534-539

21. Dedov I.I., Shestakova M.V., Mayorov A.Y. et al. Diabetes mellitus type 2 in adults. Diabetes mellitus. 2020;23(2S):4-102. (In Russ.) doi:10.14341/DM12507

22. Witteles RM, Fowler MB. Insulin-Resistant Cardiomyopathy: Clinical Evidence, Mechanisms, and Treatment Options. Journal of the American College of Cardiology, 2008; Vol. 51, No. 2: 93-102. doi:10.1016/j.jacc.2007.10.021

23. Tsanava I.A., Sharonova L.A., Verbovoy A.F. Metabolic syndrome and cardiovascular diseases. RMJ. 2017; 11:785–789. (In Russ.).

24. Roitman A.P., Fedorova T.A., Ivanova E.A. et al. The role of metabolism disorders, inflammation, myocardial injury in development chronic heart failure in metabolic syndrome patients. Laboratory Service. 2018; 7(4): 5‑10. (In Russ.). doi:10.17116/labs201870415)

25. Drapkina O.M., Ivashkin V.T., Korneeva O.N. Klinicheskie varianty metabolicheskogo sindroma. MIA. M., 2011. 220p. (In Russ.).

26. Markova T.N., Mishchenko N.K., Petina D.V. Adipocytokines: modern definition, classification and physiological role. Problems of Endocrinology. 2022;68(1):73-80. (In Russ.). doi:10.14341/probl12805

27. Litvinova L.S., Vasilenko M.A., Zatolokin P.A. et al. Adipokines in metabolic processes regulating during obesity treatment. Diabetes mellitus. 2014;17(3):51-59. (In Russ.) doi:10.14341/DM2014351-59

28. Ohtsuki T., Satoh K., Shimizu T. et al. Identification of adipsin as a novel prognostic biomarker in patients with coronary artery disease. J Am Heart Assoc. 2019, 8: e013716. doi:10.1161/JAHA.119.013716

29. Man W., Song X., Xiong Z. et al. Exosomes derived from pericardial adipose tissues attenuate cardiac remodeling following myocardial infarction by Adipsin-regulated iron homeostasis. Front Cardiovasc Med. 2022; 9: 1003282. doi:10.3389/fcvm.2022.1003282.

30. Woo J.S., Kim W., Ha S.J. et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arteriosclerosis, Thrombosis, and Vascular Biology. 2013;33(9):2252–2260. doi:10.1161/ATVBAHA.113.301586

31. Ussher J.R., Drucker D.J. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33(2):187-215. doi:10.1210/er.2011-1052

32. Sivertsen J., Rosenmeier J., Holst J.J. et al. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol. 2012;9(4):209-222. Published 2012 Jan 31. doi:10.1038/nrcardio.2011.211

33. Ussher J.R., Baggio L.L., Campbell J.E. et al. Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. Mol Metab 2014; 3(5): 507-17. doi:10.1016/j.molmet.2014.04.009.

34. Mahmoodi M.R., Najafipour H. Association of C-peptide and lipoprotein(a) as two predictors with cardiometabolic biomarkers in patients with type 2 diabetes in KERCADR population-based study. PLoS One. 2022; 17(5): e0268927. doi: 10.1371/journal.pone.0268927.

35. Kazafeos K. Incretin effect: GLP-1, GIP, DPP4. Diabetes Res Clin Pract. 2011; 93 Suppl 1: S32-36. doi:10.1016/S0168-8227(11)70011-0.

36. Hiromura M., Mori Y., Kohashi K., et al. Suppressive Effects of Glucose-Dependent Insulinotropic Polypeptide on Cardiac Hypertrophy and Fibrosis in Angiotensin II-Infused Mouse Models. Circ J. 2016; 80(9): 1988-97. doi:10.1253/circj.CJ-16-0152.

37. Hiromura M., Mori Y., Terasaki M. et al. Glucose-dependent insulinotropic polypeptide inhibits cardiac hypertrophy and fibrosis in diabetic mice via suppression of TGF-β2. Diab Vasc Dis Res. 2021; 18(2): 1479164121999034. doi:10.1177/1479164121999034.

38. Greenwell A.A., Chahade J.J., Ussher J.R. Cardiovascular biology of the GIP receptor. Peptides. 2020; 125: 170228. doi:10.1016/j.peptides.2019.170228.